

1. Identification

Product identifier	Pravastatin Sodium	
Other means of identification		
Catalog number	1554206	
CAS number	81131-70-6	
Synonyms	Eptastatin sodium * 3beta-hydroxycompactin sodium salt	
Chemical name	Sodium (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[[[(S)-2-methylbutanoyl]oxy]-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoate	
Recommended use	Specified quality tests and assay use only.	
Recommended restrictions	Not for use as a drug. Not for administration to humans or animals.	
Manufacturer/Importer/Supplier/Distributor information		
Manufacturer		
Company name	U. S. Pharmacopeia	
Address	12601 Twinbrook Parkway Rockville MD 20852-1790 United States	
Telephone	RS Technical Services	301-816-8129
Website	www.usp.org	
E-mail	RSTECH@usp.org	
Emergency phone number	CHEMTREC within US & Canada	1-800-424-9300
	CHEMTREC outside US & Canada	+1 703-527-3887

2. Hazard(s) identification

Physical hazards	Not classified.	
Health hazards	Reproductive toxicity	Category 1B
Environmental hazards	Not classified.	
OSHA defined hazards	Not classified.	
Label elements		



Signal word	Danger
Hazard statement	May damage fertility or the unborn child.
Precautionary statement	
Prevention	Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Wear protective gloves/protective clothing/eye protection/face protection.
Response	If exposed or concerned: Get medical advice/attention.
Storage	Store locked up.
Disposal	Dispose of contents/container in accordance with local/regional/national/international regulations.
Hazard(s) not otherwise classified (HNOC)	None known.
Supplemental information	Pharmacologically active material.

3. Composition/information on ingredients

Substance

Chemical name	Common name and synonyms	CAS number	%
Pravastatin Sodium	Eptastatin sodium 3beta-hydroxycompactin sodium salt	81131-70-6	100

4. First-aid measures

Inhalation	Move to fresh air. Call a physician if symptoms develop or persist.
Skin contact	Rinse skin with water/shower. Get medical attention if irritation develops and persists.
Eye contact	Rinse with water. Get medical attention if irritation develops and persists.
Ingestion	Rinse mouth. If ingestion of a large amount does occur, call a poison control center immediately.
Most important symptoms/effects, acute and delayed	Muscle weakness. Pharmacologically active material. Occupational exposure may cause physiological effects.
Indication of immediate medical attention and special treatment needed	Provide general supportive measures and treat symptomatically. Treatment of statin overdose may include the following: Administer activated charcoal as an aqueous slurry. For rhabdomyolysis, administer 0.9% saline to maintain urine output of 2 - 3 milliliters/kg/hour. Monitor fluid balance, serum electrolytes, CPK, liver enzymes, and renal function. Administer diuretics if needed to maintain urine output. Urinary alkalinization is not recommended. Hemodialysis is not expected to enhance clearance.
General information	Remove from exposure. Remove contaminated clothing. For treatment advice, seek guidance from an occupational health physician or other licensed health-care provider familiar with workplace chemical exposures. In the United States, the national poison control center phone number is 1-800-222-1222. If person is not breathing, give artificial respiration. If breathing is difficult, give oxygen if available. Persons developing serious hypersensitivity (anaphylactic) reactions must receive immediate medical attention.

5. Fire-fighting measures

Suitable extinguishing media	Water. Foam. Dry chemical or CO2. Use fire-extinguishing media appropriate for surrounding materials.
Unsuitable extinguishing media	None known.
Specific hazards arising from the chemical	No unusual fire or explosion hazards noted.
Special protective equipment and precautions for firefighters	Wear suitable protective equipment.
Fire fighting equipment/instructions	Use water spray to cool unopened containers. As with all fires, evacuate personnel to a safe area. Firefighters should use self-contained breathing equipment and protective clothing.
Specific methods	Use standard firefighting procedures and consider the hazards of other involved materials.
General fire hazards	No unusual fire or explosion hazards noted.

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures	Keep unnecessary personnel away. Wear appropriate personal protective equipment. Avoid inhalation of dust from the spilled material. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Ensure adequate ventilation. For personal protection, see section 8 of the SDS.
Methods and materials for containment and cleaning up	For waste disposal, see section 13 of the SDS. Avoid the generation of dusts during clean-up. Sweep up or vacuum up spillage and collect in suitable container for disposal. Clean surface thoroughly to remove residual contamination.
Environmental precautions	Avoid discharge into drains, water courses or onto the ground.

7. Handling and storage

Precautions for safe handling	As a general rule, when handling USP Reference Standards, avoid all contact and inhalation of dust, mists, and/or vapors associated with the material. Clean equipment and work surfaces with suitable detergent or solvent after use. After removing gloves, wash hands and other exposed skin thoroughly. Select and use containment devices and personal protective equipment based on a risk assessment of material potency and exposure potential.
Conditions for safe storage, including any incompatibilities	Store in tight container as defined in the USP-NF. This material should be handled and stored per label instructions to ensure product integrity.

8. Exposure controls/personal protection

Occupational exposure limits	No exposure limits noted for ingredient(s).
Biological limit values	No biological exposure limits noted for the ingredient(s).
Appropriate engineering controls	For laboratory operations, use local exhaust ventilation or a ventilated enclosure for high energy operations such as particle sizing. Control exposures to below the occupational exposure level (if available). Select and use containment devices and personal protective equipment based on a risk assessment of exposure potential. Cover all containers for solutions and slurries while being transferred.
Individual protection measures, such as personal protective equipment	
Eye/face protection	Wear safety glasses with side shields, chemical splash goggles, or full face shield, if necessary. Base the choice of protection on the job activity and potential for contact with eyes or face. An emergency eye wash station should be available.
Skin protection	
Hand protection	Wear nitrile or other impervious gloves if skin contact is possible. When the material is dissolved or suspended in an organic solvent, wear gloves that provide protection against the solvent.
Other	Train employees in proper gowning and degowning practices. Wear lab coat. Base the choice of skin protection on the job activity, potential for skin contact and solvents and reagents in use. Do not wear protective garments in common areas (e.g., cafeterias) or out-of-doors.
Respiratory protection	Respirators are generally not required for laboratory operations. Use a tight-fitting full-face respirator with HEPA filters for spill cleanup. Chose respiratory protection appropriate to the task and the level of existing engineering controls.
Thermal hazards	Wear appropriate thermal protective clothing, when necessary.
General hygiene considerations	Handling practices in this SDS are recommendations for laboratory use of reference standards. Procedures for any other uses or quantities should be determined after an appropriate assessment.

9. Physical and chemical properties

Appearance	Appearance descriptions are general information and not specific to any USP lot.
Physical state	Solid.
Form	Crystalline powder.
Color	White. Yellow.
Odor	Odorless.
Odor threshold	Not available.
pH	Not available.
Melting point/freezing point	280.4 - 287.6 °F (138 - 142 °C)
Initial boiling point and boiling range	Not available.
Flash point	Not available.
Evaporation rate	Not available.
Flammability (solid, gas)	Not available.
Upper/lower flammability or explosive limits	
Flammability limit - lower (%)	Not available.
Flammability limit - upper (%)	Not available.
Explosive limit - lower (%)	Not available.
Explosive limit - upper (%)	Not available.
Vapor pressure	< 0.0000001 kPa at 25 °C
Vapor density	Not available.
Relative density	Not available.
Solubility(ies)	
Solubility (water)	Freely soluble.
Solubility (other)	Methanol: Freely soluble. Ethanol: Soluble. Isopropanol: Soluble. Acetonitrile: Very slightly soluble.

	Acetone: Practically insoluble. Chloroform: Practically insoluble. Ethyl acetate: Practically insoluble. Ether: Practically insoluble.
Partition coefficient (n-octanol/water)	0.59 at pH 7
Auto-ignition temperature	755.06 °F (401.7 °C)
Decomposition temperature	Not available.
Viscosity	Not available.
Other information	
Molecular formula	C ₂₃ H ₃₅ NaO ₇
Molecular weight	446.52
pH in aqueous solution	7.2 - 9 Solution: 5%

10. Stability and reactivity

Reactivity	The product is stable and non-reactive under normal conditions of use, storage and transport.
Chemical stability	Material is stable under normal conditions.
Possibility of hazardous reactions	No dangerous reaction known under conditions of normal use.
Conditions to avoid	Contact with incompatible materials.
Incompatible materials	Oxidizing agents.
Hazardous decomposition products	Na. Irritating and/or toxic fumes or gases. Emits toxic fumes under fire conditions.

11. Toxicological information

Information on likely routes of exposure

Inhalation	Knowledge about health hazard is incomplete.
Skin contact	Knowledge about health hazard is incomplete.
Eye contact	Knowledge about health hazard is incomplete.
Ingestion	Based on information from therapeutic use, this material may cause: Muscle weakness.
Symptoms related to the physical, chemical, and toxicological characteristics	Statins: Muscle pain or weakness. Mood or mental changes. Memory loss and confusion. Skin rash. Gastrointestinal disturbances. Hyperglycemia.

Information on toxicological effects

Acute toxicity

Product	Species	Test Results
Pravastatin Sodium (CAS 81131-70-6)		
Acute		
Oral		
LD50	Mouse	8939 mg/kg
	Rat	> 12 g/kg

Skin corrosion/irritation Knowledge about health hazard is incomplete.

Serious eye damage/eye irritation Knowledge about health hazard is incomplete.

Respiratory or skin sensitization

Respiratory sensitization Knowledge about health hazard is incomplete.

Skin sensitization Knowledge about health hazard is incomplete.

Germ cell mutagenicity Based on available data, the classification criteria are not met.

Mutagenicity

Ames test (Salmonella typhimurium; E. coli)
Result: Negative.
Dominant lethal test
Result: Negative.
Species: Mouse

Mutagenicity

Micronucleus assay
Result: Negative.
Species: Mouse
Mutagenicity: Chromosomal aberration assay in cells
Result: Negative.
Species: Hamster
Mutagenicity: Forward mutation assay in mouse lymphoma cells
Result: Negative.
Mutagenicity: Gene conversion test in *S. cerevisiae*
Result: Negative.

Carcinogenicity

Based on available data, the classification criteria are not met.

Although statins have been carcinogenic in animal studies, the relevance of this to humans has been questioned. Studies of human data have not shown an association between use of statins and the incidence of cancer.

10 - 100 mg/kg Carcinogenicity, administered orally
Result: Increased incidence of hepatocellular carcinomas in males at the high doses.
Species: Rat
Test Duration: 2 years
100 mg/kg Carcinogenicity
Result: No drug-induced tumors noted.
Species: Mouse
Test Duration: 2 years
250 - 500 mg/kg/day Carcinogenicity, administered orally
Result: Increased incidence of hepatocellular carcinomas and lung adenomas.
Species: Mouse
Test Duration: 2 years

IARC Monographs. Overall Evaluation of Carcinogenicity

Not listed.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

Not regulated.

US. National Toxicology Program (NTP) Report on Carcinogens

Not listed.

Reproductive toxicity

May damage fertility or the unborn child. Therapeutic use of statins during pregnancy may decrease cholesterol and cholesterol-derived substances essential for fetal development. Results of animal studies indicate that many statins are associated with adverse fetal outcomes at maternally toxic doses.

Reproductivity

1000 mg/kg/day Reproductivity and development study
Result: Not teratogenic or embryotoxic.
Species: Rat
50 mg/kg/day Reproductivity and development study
Result: Not teratogenic or embryotoxic.
Species: Rabbit
500 mg/kg/day Reproductivity and development study
Result: No adverse effects on fertility or reproductive performance.
Species: Rat

Specific target organ toxicity - single exposure

Knowledge about health hazard is incomplete.

Specific target organ toxicity - repeated exposure

Knowledge about health hazard is incomplete.

Aspiration hazard

Based on available data, the classification criteria are not met.

Further information

Pharmacologically active material. Occupational exposure may cause physiological effects.

12. Ecological information**Ecotoxicity**

The product is not classified as environmentally hazardous. However, this does not exclude the possibility that large or frequent spills can have a harmful or damaging effect on the environment.

Persistence and degradability

No data is available on the degradability of this product.

Bioaccumulative potential

Octanol/water partition coefficient log K_{ow}

0.59, at pH 7

Mobility in soil

No data available.

Other adverse effects

No other adverse environmental effects (e.g. ozone depletion, photochemical ozone creation potential, endocrine disruption, global warming potential) are expected from this component.

13. Disposal considerations

Disposal instructions

Dispose in accordance with all applicable regulations. Under RCRA, it is the responsibility of the user of the product to determine, at the time of disposal, whether the product meets RCRA criteria for hazardous waste.

Local disposal regulations

Dispose in accordance with all applicable regulations.

Hazardous waste code

The waste code should be assigned in discussion between the user, the producer and the waste disposal company.

Waste from residues / unused products

Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see: Disposal instructions).

Contaminated packaging

Since emptied containers may retain product residue, follow label warnings even after container is emptied.

14. Transport information

DOT

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable.

General information

It is the shipper's responsibility to determine the correct transport classification at the time of shipment.

15. Regulatory information

US federal regulations

This product is a "Hazardous Chemical" as defined by the OSHA Hazard Communication Standard, 29 CFR 1910.1200.

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

CERCLA Hazardous Substance List (40 CFR 302.4)

Not listed.

SARA 304 Emergency release notification

Not regulated.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

Not regulated.

Superfund Amendments and Reauthorization Act of 1986 (SARA)

Hazard categories

Immediate Hazard - No
Delayed Hazard - Yes
Fire Hazard - No
Pressure Hazard - No
Reactivity Hazard - No

SARA 302 Extremely hazardous substance

Not listed.

SARA 311/312 Hazardous chemical

Yes

SARA 313 (TRI reporting)

Not regulated.

Other federal regulations

Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Not regulated.

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

Safe Drinking Water Act (SDWA) Not regulated.

US state regulations

US - California Proposition 65 - CRT: Listed date/Developmental toxin

Pravastatin Sodium (CAS 81131-70-6)

Listed: March 3, 2000

International Inventories

Country(s) or region	Inventory name	On inventory (yes/no)*
Australia	Australian Inventory of Chemical Substances (AICS)	No
Canada	Domestic Substances List (DSL)	No
Canada	Non-Domestic Substances List (NDSL)	No
China	Inventory of Existing Chemical Substances in China (IECSC)	No
Europe	European Inventory of Existing Commercial Chemical Substances (EINECS)	No
Europe	European List of Notified Chemical Substances (ELINCS)	No
Japan	Inventory of Existing and New Chemical Substances (ENCS)	No
Korea	Existing Chemicals List (ECL)	No
New Zealand	New Zealand Inventory	Yes
Philippines	Philippine Inventory of Chemicals and Chemical Substances (PICCS)	No
United States & Puerto Rico	Toxic Substances Control Act (TSCA) Inventory	No

*A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s)

A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).

16. Other information, including date of preparation or last revision

Issue date 02-09-2009

Revision date 09-19-2018

Version # 04

Disclaimer USP Reference Standards are sold for chemical test and assay purposes only, and NOT for human consumption. The information contained herein is applicable solely to the chemical substance when used as a USP Reference Standard and does not necessarily relate to any other use of the substance described, (i.e. at different concentrations, in drug dosage forms, or in bulk quantities). USP Reference Standards are intended for use by persons having technical skill and at their own discretion and risk. This information has been developed by USP staff from sources considered reliable but has not been independently verified by the USP. Therefore, the USP Convention cannot guarantee the accuracy of the information in these sources nor should the statements contained herein be considered an official expression. NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE is made with respect to the information contained herein.